BrainStorm Cell Therapeutics Receives FDA Clearance for ALS Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a pioneer in stem cell therapies targeting neurodegenerative disorders, recently achieved a significant milestone. The U.S. Food and Drug Administration (FDA) has granted the company clearance to commence its Phase 3b clinical trial of NurOwn®, a promising treatment for amyotrophic lateral sclerosis (ALS).
Overview of the Phase 3b Clinical Trial
The FDA's clearance allows BrainStorm to initiate a clinical trial as per an agreement established through a Special Protocol Assessment (SPA), which is instrumental in validating the study's structure and endpoints. This trial will focus on gathering data crucial for a future Biologics License Application (BLA) submission, and it marks a critical advancement for potential ALS therapies.
Details of the Trial Design
In this trial, approximately 200 participants will be recruited from top academic medical centers. The design includes a 24-week randomized, double-blind, placebo-controlled phase followed by an additional 24-week open-label extension, during which all participants will receive NurOwn®. The prime outcome measure will be the change in the ALS Functional Rating Scale-Revised (ALSFRS-R) from baseline to week 24.
Words from Leadership
Chaim Lebovits, President and Chief Executive Officer of BrainStorm, emphasized the significance of the FDA's clearance: "This FDA clearance is a defining milestone for BrainStorm and the ALS community. We are now positioned to swiftly activate clinical sites in a phased manner and diligently prepare to enroll the first patient in the Phase 3b trial." He also mentioned the ongoing efforts to secure funding from diverse sources to support the successful launch of this vital study.
Importance of NurOwn® in ALS Treatment
NurOwn® represents BrainStorm's lead investigational therapy aimed at treating ALS. Utilizing autologous mesenchymal stem cells (MSCs), the therapy is designed to produce cells that secrete neurotrophic factors, which may address neuroinflammation and promote neuroprotection. The therapy has been granted Orphan Drug designation by both the FDA and the European Medicines Agency (EMA).
Progress and Learnings from Previous Trials
BrainStorm has also completed a Phase 3 trial for ALS, yielding valuable insight into the disease's biology and treatment response. Insights gained from pharmacogenomic responses, biomarker data, and challenges associated with clinical outcomes have been documented extensively in peer-reviewed journals.
Broader Implications of BrainStorm's Research
Beyond ALS, BrainStorm has initiated a Phase 2 open-label trial of MSC-NTF cells for progressive multiple sclerosis, which highlights the company's commitment to expanding its research portfolio. Furthermore, they are in the process of developing Allogeneic exosome-based therapies, supported by a recent Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent related to this innovative technology.
Continued Engagement and Developing Updates
BrainStorm management is set to discuss these pivotal advancements in the upcoming corporate update call and webcast. This event will take place on the shores of their commitment to transparency and engagement, with further updates to be announced as the trial progresses and key milestones are reached.
Frequently Asked Questions
What is NurOwn® and how does it work?
NurOwn® is a stem cell therapy developed by BrainStorm that uses autologous mesenchymal stem cells to produce cells that secrete neurotrophic factors, which assist in reducing neuroinflammation and enhancing neuroprotection.
What are the goals of the Phase 3b trial?
The Phase 3b trial aims to evaluate the efficacy of NurOwn® in ALS patients by measuring functional changes in participants over a 24-week period.
How many participants will be involved in the trial?
Approximately 200 participants will be enrolled in the trial, which will occur at leading academic medical centers.
What funding strategies is BrainStorm considering for the trial?
BrainStorm is exploring various funding sources, including non-dilutive grants, to ensure the timely and successful launch of the trial.
What does FDA clearance mean for BrainStorm and ALS patients?
The FDA's clearance represents a significant step forward for BrainStorm's ALS therapy and brings hope for improved treatment options for patients suffering from this devastating disease.
